Our study was carried out to evaluate the effect of Chrysanthemum ethanolic extract on some hematological parameters in the anticancer drug capecitabine (XELODA^®) exposed male rats using comet assay and biochemical changes. Thirty-six albino rats were divided into 6 groups (6 animals each) as follows:1) capecitabine group (xeloda at a dose of 30 mg/kg bw as a positive control); 2) capecitabine + chrysanthemum 5 mg/kg); 3) capecitabine (Xeloda) + Chrysanthemum (10 mg/kg); 4) Chrysanthemum (5 mg/kg) 5) Chrysanthemum (10 mg/kg); 6) Control group (negative control) for 45 days. The results of this study led to the following: capecitabine (Xeloda)treatment induces a decrease in RBCS, leukocytes, and platelets count, level of Hgb and Hct, while the use of capecitabine (Xeloda)in combination with Chrysanthemum improved these alterations, especially with the high dose of Chrysanthemum. Finally, the data suggest that the synchronous use of Chrysanthemum with capecitabine (Xeloda) treatment will be useful to decrease the side effects of capecitabine.